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Abstract
Objective—Treatment guidelines suggest distinctive medication strategies for first episode and 
multi-episode patients with schizophrenia. How much community clinicians adjust their usual 
treatment regimens for first episode patients is unknown. We examined prescription patterns and 
factors associated with prescription choice within a national cohort of early phase patients.
Method—Study entry prescription data (before any influence on treatment by study procedures) 
were obtained from 404 participants in the RAISE-ETP study, a US nationwide effectiveness 
study conducted at 34 community treatment centers in 21 states for patients with first episode 
schizophrenia-spectrum disorders. Subjects had been treated with antipsychotics for 6 months or 
less at study entry.
Results—We identified 159 subjects (39.4% of the sample) who might benefit from changes in 
their psychotropic prescriptions. Of these 159 subjects, 8.8% were prescribed recommended 
antipsychotics at higher than recommended doses, 32.1% were prescribed olanzapine (often at 
high doses), 23.3% more than one antipsychotic, 36.5% an antipsychotic but also an 
antidepressant without a clear indication, 10.1% psychotropic medications without an 
antipsychotic and 1.2% stimulants.
Multivariate analyses found evidence for sex, age and insurance status effects on medication 
prescription. Racial and ethnic effects consistent with effects found in prior multi-episode studies 
were found in univariate analyses. There were some regional variation in prescription practices; 
when present, regional patterns varied across prescribing practices. Diagnosis had limited, and 
inconsistent, effects.
Conclusions—Besides prescriber education, policy makers may need to consider not only 
patient factors but also service delivery factors in efforts to improve first episode prescription 
practices.
Clinical Trials registration—NCT01321177: An Integrated Program for the Treatment of First 
Episode of Psychosis (RAISE ETP), http://www.clinicaltrials.gov/ct2/show/NCT01321177
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Research supports different medication treatment approaches for first episode and multi-
episode schizophrenia (reviewed (1)) and recent schizophrenia treatment practice guidelines 
(e.g (2–6)) include specific first episode recommendations. Since the incidence of 
schizophrenia is low (7), most clinicians’ experience outside of specialty centers is heavily 
weighted towards the treatment of multi-episode patients. How much community clinicians 
adjust their treatment regimens for first episode patients is unknown.
The Early Treatment Program (ETP) study, a nationwide comparative effectiveness trial that 
is part of the National Institute of Mental Health Recovery After an Initial Schizophrenia 
Episode (RAISE) initiative, provided the basis for the first national report of U.S. 
community mental health center medication treatments for the crucial early phase of 
schizophrenia. We addressed two questions: what are the medication treatments currently 




RAISE-ETP compares NAVIGATE, a coordinated specialty care treatment program for first 
episode psychosis that includes medical management guided by a decision support system, 
individual therapy, family psychoeducation, and supported employment and education, and 
Community Care, treatment determined by clinician choice. RAISE-ETP was conducted 
under the guidance of the respective institutional review boards for the coordinating center 
and the sites.
The design prioritized enhancing generalizability of findings to community settings. 
Inclusion/exclusion criteria were chosen to allow broad inclusion of different patient 
subgroups. Inclusion criteria were: age 15 to 40 years; diagnosis of schizophrenia, 
schizophreniform disorder, schizoaffective disorder, psychosis NOS or brief psychotic 
disorder; beginning first treatment for psychosis (defined as having taken antipsychotic 
medications cumulatively for 6 months or less) and ability to participate in research 
assessments in English. Exclusion criteria were: had clearly experienced more than one 
discrete psychotic episode; diagnosis of bipolar disorder, psychotic depression, substance-
induced psychotic disorder or current psychotic disorder due to a general medical condition; 
presence of current neurological disorders that would affect diagnosis or prognosis; 
clinically significant head trauma or other serious medical conditions that would 
significantly impair assessment, functioning or treatment. All subjects provided written 
informed consent (or written assent for those under age 18 along with parent’s/guardian’s 
written consent).
We employed site randomization to facilitate participation by sites without previous research 
experience, to eliminate potential treatment strategy “spillover” effects and to enhance study 
acceptability by patients who would not need to agree to individual randomization. Thirty-
four sites in 21 states were selected after a national search. All were community treatment 
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centers with no preexisting first episode program. Sites were intentionally located in diverse 
settings, ranging from large urban to rural settings. Seventeen sites were randomized to 
deliver NAVIGATE treatment and 17 to Community Care.
RAISE-ETP data specific to this report were collected between July 2010 and July 2012.
RAISE-ETP assessments pertinent to this report: Site staff obtained medication data using 
all available sources of information including direct interview with subjects and their 
families (if available) and record review. Medication history collection was a priority in 
order to establish study eligibility that specified maximum antipsychotic treatment duration. 
We present data on psychotropic medications being prescribed (even if not actually taken) to 
subjects at study entry and before any influence on treatment by study guidelines or 
procedures. Diagnoses were determined using the Structured Clinical Interview for Axis 1 
DSM-IV Disorders Patient Edition (SCID) (8) administered by masked remote assessors via 
live, two-way video. Information sources were the subjects and a structured summary of 
subject symptoms and treatment history provided to the assessor prior to the SCID 
interview. Tobacco smoking status was assessed with the Fagerstrom (9) questionnaire. Data 
about recent alcohol and substance use was obtained by clinic staff using record review and 
direct interview of patients and their families (if available).
Statistical analyses
Prescribing patterns were characterized using standard descriptive methods (e.g. 
percentages). Potential correlates for the analyses of prescribing patterns were chosen based 
on the following. Sex (10), racial background (11–13) and ethnicity (14) influence 
antipsychotic response or prescription patterns with multi-episode patients. Cigarette 
smoking decreases blood levels of some psychotropics (15). Age was included because 
some agents have adolescent indications. Prior depressive or anxiety symptoms should 
influence antidepressant prescription. Prescription may differ among the various 
schizophrenia-spectrum disorders or by the presence of concurrent substance use. Insurance 
status influences access to particular medications and also treatment settings in the U.S. Our 
data from 21 states allowed us to examine regional variations in prescription. We examined 
these factors in relation to nine key prescription practices: antipsychotic prescription, 
prescription of more than one antipsychotic, long acting injectable antipsychotic 
prescription, first generation antipsychotic prescription, risperidone prescription and dose, 
olanzapine prescription and dose and antidepressant prescription.
We adopted a Bayesian perspective for the correlates analyses. As an aid to readers 
unfamiliar with Bayesian analyses, we review some features of Bayesian analyses. Bayesian 
analyses do not require correction for multiple comparisons (16). Bayesian credible intervals 
(CrIs) are similar to confidence intervals (CI) in classical analyses, but in the Bayesian 
framework, the interval contains the true population parameter. Bayesian analyses do not 
generate p-values. Instead, the posterior probability of being a risk factor (PPRF), also 
sometimes referred to as selected %, is the probability that a variable is associated with an 
outcome. The larger the PPRF, the stronger the evidence for an association. We present 
PPRF evidence classifications adapted from (17,18): <50% lacking evidence, 50–75% some 
evidence, 75–95% positive evidence, 95–99% strong evidence and >99% very strong 
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evidence for an association with outcomes. Studies (18) comparing results from classical 
and Bayesian analyses provide additional context for PPRF interpretation. These studies 
show that variables that are not significant in classical analyses have Bayesian PPRFs of less 
(often much less) than 50%.
For all analyses, a weakly informative prior distribution was constructed by first scaling all 
non-binary variables to have mean 0 and standard deviation 0.5, and then placing an 
independent distribution from the Student t prior family (specifically, a Cauchy distribution 
centered at zero and 2.5 scale) on the coefficients (19). This prior has the advantage of 
always giving solutions even when there is complete separation in the logistic regression 
(20,21). Univariate analysis was done using the bayesglm function in the arm package in R; 
sim function was used to obtain simulates of the posterior distribution of each coefficient in 
the general linear model, and 95% Crls were obtained based on the 2.5th and 97.5th 
percentiles of the posterior distribution. Multivariate analyses employed Bayesian model 
averaging (BMA), a Bayesian solution to the problem of inference in the presence of 
multiple competing models (18). The bic.glm function from R package BMA was primarily 
used for these analyses.
Results
Subjects
The CONSORT diagram Supplemental Figure 1 presents the enrollment flow. The sample 
included 404 subjects. Community centers normally do not do outreach; new patients arrive 
through referral from inpatient units, other clinicians or self-referral. This pattern mostly 
held for the study; 335 (83%) subjects came from these sources and only 88 (17%) from 
outreach activities (e.g. educating the professional community about RAISE-ETP; 
educational efforts with potential patients and their families through articles in the local 
press, information booths at community events). As shown in Table 1, most subjects had a 
psychiatric hospitalization before study entry. Subjects were mostly young, male and from 
diverse racial backgrounds. Approximately half met DSM-IV criteria for schizophrenia; the 
next most common diagnoses were schizophreniform disorder and schizoaffective disorder. 
Consistent with early phase illness, mean cumulative lifetime antipsychotic treatment was 
only 46.7 (95% CI: 42.2, 51.2) days.
The frequency of prescription of major medication classes is presented in Table 2
Most subjects were prescribed antipsychotics and approximately a third of subjects were 
prescribed antidepressants.
Subjects not prescribed antipsychotic medications at study entry
All subjects had a psychotic disorder for which antipsychotic treatment is indicated. Fifty-
one (12.6%) subjects were not prescribed any psychotropic medications at study entry. 
Twenty-four (47.1%) of these had had a psychiatric inpatient admission and 16 (31.4%) had 
taken antipsychotics in the past. Sixteen subjects were prescribed psychotropic medications 
but not antipsychotics. Fourteen of these were prescribed antidepressants, 1 clonazepam and 
1 clonidine.
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Of the 337 subjects prescribed an antipsychotic, only 40 (11.9%) were prescribed a first 
generation agent, including subjects prescribed both a first and a second generation 
antipsychotic. Long acting injectable antipsychotics were prescribed for 32 (9.5%) of the 
337 subjects who were prescribed antipsychotics. Frequency of long acting injectable 
prescription was: paliperidone palmitate 17 (53.1% of long acting prescriptions); 11 (34.4%) 
haloperidol decanoate; 3 (9.4%) risperidone microspheres and 1 (3.1%) for fluphenazine 
decanoate.
Antipsychotic monotherapy was by far the most common pattern. Three hundred (89.0%) of 
the 337 subjects prescribed antipsychotics were prescribed only one antipsychotic (either in 
single or multiple formulations), 35 (10.4%) were prescribed 2 different antipsychotics and 
2 (0.6%) were prescribed 3 different antipsychotics.
Prescriptions for antipsychotic monotherapy—As shown in Table 3, risperidone 
accounted for approximately one-third of the 300 prescriptions for antipsychotic 
monotherapy. The next most commonly prescribed antipsychotic was olanzapine (17.0% of 
prescriptions) followed by aripiprazole, paliperidone and quetiapine each accounting for 
around 10% of prescriptions.
First episode schizophrenia treatment guidelines emphasize using low-dose strategies. As 
shown in Table 3, relatively few subjects were prescribed antipsychotic doses higher than 
the suggested 2009 PORT (4) upper dosing limit for multi-episode patients. High dose 
strategies were found for only certain medications, notably olanzapine. 44.9% of olanzapine 
prescriptions were above specific 2009 PORT guidelines (4) for first episode treatment 
compared with only 7.8% of risperidone prescriptions.
Prescriptions for two or more antipsychotics—Prescriptions for multiple 
antipsychotics included combinations of 13 different antipsychotics. The most commonly 
prescribed agents were: risperidone prescribed to 16 (43.2%) of the 37 subjects prescribed 
multiple agents; quetiapine prescribed to 13 (35.1%) subjects; olanzapine prescribed to 10 
(27.0%); aripiprazole to 9 (24.3%) and haloperidol to 8 (21.6%).
Medications for motor side effects—We lack data on perceived indications for 
prescriptions but anti-cholinergic medications and beta blockers are usually prescribed for 
motor side effects in patients taking antipsychotics. 71 (21.1%) of the 337 subjects 
prescribed an antipsychotic were concurrently prescribed an anti-cholinergic medication and 
7 (2.1%) a beta blocker. Anti-anxiety agents can be prescribed for motor side effects and/or 
for anxiety. Thirty-nine (11.6%) of the 337 were prescribed an anti-anxiety agent.
Antidepressants prescribed with antipsychotics—One hundred fifteen subjects 
were prescribed both an antidepressant and an antipsychotic. Only 57 (49.6%) of the 115 
had any SCID interview documentation of lifetime depression (i.e. major depression, 
depressive disorder NOS, schizoaffective disorder, depressive type) or anxiety (i.e. panic 
disorder, social phobias, obsessive-compulsive disorder, post traumatic stress disorder, 
generalized anxiety disorder, anxiety due to a medical condition, anxiety disorder NOS) that 
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might broadly be considered justification for antidepressant treatment. Although not 
recommended by treatment guidelines, antidepressants are sometimes prescribed for 
negative symptoms. However, only 6 (10.3%) of the remaining 58 subjects prescribed 
antidepressants had any prominent negative symptoms by SCID interview.
Factors associated with prescribing patterns
These analyses are summarized in main text Figure 1 and 2 and presented in detail in 
Supplemental Materials Tables 1 and 2. Antipsychotic prescription. Univariate but not 
multivariate analyses (all PPRFs <21.2%; all lacking evidence) suggested that women and 
subjects with public versus private insurance were less likely to receive an antipsychotic 
while those with schizophreniform versus schizophrenia or schizoaffective disorder were 
more likely to receive an antipsychotic prescription. Prescriptions for two or more 
antipsychotics were more likely for subjects at southern versus Midwestern sites in 
univariate but not multivariate analyses (PPRF=4.6%; lacking evidence). In multivariate 
analyses subjects with private insurance were less likely to be prescribed more than one 
antipsychotic than either subjects with public (PPRF=52.9%; some evidence) or no 
insurance (PPRF=51.9%; some evidence). Long acting injectable prescription was more 
frequent for women and subjects at Midwestern versus western sites based upon univariate 
but not multivariate analyses (PPRF=40.2% and 20.9%, respectively; both lacking 
evidence). First generation antipsychotic prescription. Multivariate analyses showed that 
first generation antipsychotic prescription was more common among the uninsured versus 
those with private (PPRF=96.2%; strong evidence) or public insurance (PPRF=56.4%; some 
evidence); African Americans were more likely than Caucasians to be prescribed first 
generation antipsychotics based upon univariate but not multivariate analyses 
(PPRF=23.1%; lacking evidence). Risperidone prescription. Multivariate analyses revealed 
that younger subjects (PPRF=66.4%; some evidence) and univariate analyses only that 
Hispanics (PPRF=17.5%; lacking evidence) and other racial groups (PPRF=17.5%; lacking 
evidence) versus Caucasians were more likely to be prescribed risperidone. Risperidone 
dose. Women received lower risperidone doses than men (PPRF=52.2%; some evidence). 
Univarite but not multivariate analyses (all PPRFs <17%; all lacking evidence) showed that 
subjects with psychosis NOS or schizoaffective disorder versus those with schizophrenia as 
well as those with public versus no insurance were prescribed lower risperidone doses. 
Olanzapine prescription in univariate but not multivariate analyses (all PPRFs <24%; all 
lacking evidence) was more likely among subjects at western versus southern sites and 
among those with schizophrenifrom disorder versus psychosis NOS or schizophrenia. 
Olanzapine dose was lower among women than men and for those with schizoaffective 
disorder versus psychosis NOS based upon univariate but not multivariate analyses 
(PPRFs=47.7% and 9.7%, respectively; all lacking evidence). Antidepressant prescription 
was more likely among women (PPRF=83.5%; positive evidence) and those with depression 
or anxiety symptoms (PPRF=87.1%; positive evidence); older subjects and those with 
schizoaffective disorder versus psychosis NOS were more likely to receive antidepressants 
based upon univariate analyses only (PPRF=23.8% and 1.6%, respectively; all lacking 
evidence).
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Subjects who might benefit from prescription modifications
These analyses excluded subjects not being prescribed psychotropic medications at baseline 
as some would not be expected to have prescriptions (e.g. someone initiating psychiatric 
treatment at study entry). One hundred fifty-nine subjects (39.4% of the entire sample) met 
criterion for potential benefit. Of these, 14 (8.8%) were prescribed recommended 
antipsychotics at higher than recommended doses, 51 (32.1%) were prescribed olanzapine 
(often at high doses), 37 (23.3%) more than one antipsychotic, 58 (36.5%) an antipsychotic 
but also an antidepressant without a clear indication, 16 (10.1%) psychotropic medications 
without an antipsychotic and 5 (1.2%) stimulants.
Discussion
This is the first report of psychotropic medication treatment of people with first episode 
schizophrenia-spectrum disorders in US community mental health settings. The Tiihonon 
national Finnish discharge registery study (22) provides an international comparison. Both 
studies found similar prescription rates for long acting injectables and for multiple 
antipsychotics. Risperidone followed by olanzapine were the most commonly used oral 
antipsychotics in both countries. Clozapine use was much higher in Finland. This may 
reflect different treatment practices or the possibility that more of the Finnish subjects failed 
to respond to other antipsychotics during outpatient treatment before cohort identification 
based upon their first hospitalization.
Practice guidelines (e.g. (2–6)) with specific first-episode recommendations and first-
episode research data support 1) the need for antipsychotic treatment, 2) using low 
antipsychotic dosing and 3) the need to minimize side effects, especially metabolic ones, 
during early phase treatment. Did community clinicians follow these core principles? The 
need for antipsychotic treatment was widely recognized. Only 16 subjects were not being 
prescribed antipsychotics who clearly had been evaluated for psychiatric problems as 
evidenced by the prescription for a psychotropic agent. Another 35 subjects were not 
prescribed any psychotropics; how many had recently seen a prescriber who did not 
recognize a need for psychotropic agents is unknown. Antipsychotic prescriptions were 
mostly concordant with recommendations. An exception was the relatively common use 
(17.0% of antipsychotic prescriptions) of olanzapine. Due to its more frequent adverse 
metabolic side effects (23), especially with first-episode patients (24), PORT guidelines 
recommend that olanzapine not be used for first-episode treatment. Strikingly, olanzapine 
compared with other antipsychotics was much more frequently prescribed at higher than 
recommended doses. We considered the possibility that olanzapine was prescribed for 
subjects who had not improved with other antipsychotics but the data do not support this. 
The mean days of antipsychotic treatment for subjects prescribed olanzapine (56.2 (95% CI: 
45.7, 66.7)) was similar to that for other antipsychotics (e.g. 57.8 (95% CI: 44.3, 71.3) for 
paliperidone). Regarding minimizing side effects, this requires optimizing all medications, 
not just antipsychotics. Of note, antidepressants were prescribed for around a third of 
subjects but only around half of these subjects had clear symptom indications for 
antidepressants.
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Our univariate analyses identified specific factors associated with particular prescription 
practices. Prescription maybe influenced by several factors. People designing practice 
improvement efforts may wish to focus upon factors identified by the multivariate analyses 
due to these being less biased when confounding factors are present. Both analysis types are 
informative in different contexts and we include both in our discussion. Demographic: As 
with multi-episode subjects (10), women in our sample received lower antipsychotic doses. 
They were also more likely to be prescribed a long acting injectable antipsychotic 
(univariate only) and, even controlling for depressive and anxiety symptoms, an 
antidepressant. In multi-episode studies African Americans are more likely to be prescribed 
a first generation antipsychotic (12,13) and Hispanics risperidone (25); our univariate results 
suggest that these patterns may also apply to first-episode treatment. Younger subjects were 
more likely to be prescribed risperidone, possibly because of its FDA adolescent treatment 
indication. Service delivery: We found some univariate regional differences in prescription 
practices; the regions that differed varied across prescription practices with no region 
consistently having different practices from the other regions. Insurance status effects were 
highly consistent. Private insurance was associated with better medication prescription: 
increased likelihood of antipsychotic prescription and less likelihood of receiving 2 or more 
antipsychotics or receiving a first generation antipsychotic, a medication choice discouraged 
by some (e.g. (3)) but not all (e.g. (4)) first-episode guidelines. Diagnosis: Diagnosis had no 
effect on prescription of more than 1 antipsychotic or prescription of long acting injectables, 
first generation antipsychotics or risperidone. The univariate association between 
schizoaffective diagnoses and antidepressant prescription is consistent with the mood 
symptoms required for the diagnosis; the basis for the univariate association between 
schizophreniform disorder and olanzapine prescription is unclear. Diagnostic associations 
were not consistent across analyses of risperidone and olanzapine dosing. Smoking and 
substance use was not associated with risperidone or olanzapine dosing.
Our data have limitations. Our sample may not be as generalizable as a true epidemiological 
sample despite being recruited from 34 sites in 21 states. Second, most subjects’ 
prescriptions were made at another facility, usually an inpatient unit, prior to referral to our 
study community centers. Thus, we lack data on the prescribing clinicians’ decision 
processes, their perceived indications for prescriptions and of the effects of patient 
preferences. Third, our sample’s mean total lifetime antipsychotic prescription was only 
46.7 days. For most subjects, past treatment response should not have substantially 
influenced medication selection but some subjects may have had enough treatment to 
document unusual responses to medication leading to treatment not conforming to 
guidelines. Fourth, our large number of sites prevented including individual sites in our 
analyses. Grouping sites into geographic regions provided a means to examine uniformity of 
prescribing patterns nationally, but cannot provide data on individual site practices.
Despite these limitations, our data have health policy implications. The marked use of 
second over first generation antipsychotics in our study may be warranted by evidence of 
better efficacy (26) and relapse prevention (27) and less motor side effects (26) with second 
generation antipsychotics with early phase patients. However, the marked metabolic effects 
of some second generation antipsychotics with early phase patients (28–32) suggests that 
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efforts (e.g. (33)) to increase adherence with recommended physical health monitoring of 
first-episode patients should be strongly encouraged.
Although each questionable medication practice we identified affected only between 1.2% 
to 14.4% of subjects, cumulatively 39.4% of subjects might have benefited from 
psychotropic prescriptions changes. Primary immediate targets for improving first-episode 
community treatment are discouraging use of two or more antipsychotics and the 
prescription of, and high dose of, olanzapine. Besides educational efforts to prescribers, 
changes in reimbursement models or care delivery may need to be considered to facilitate 
evidence-based treatment during the crucial early phase of schizophrenia. Subjects with 
private insurance had strikingly lower rates of prescription of two or more antipsychotics 
than patients with public or no insurance.
A large number of our subjects received antidepressants without clear indications for their 
use. Either prescribers responded to symptoms not detected by our research interviews or 
they interpreted schizophrenia symptoms as mood or anxiety symptoms. If the latter is true, 
training to improve clinicians’ ability to diagnose schizophrenia-spectrum disorders as 
distinct from mood or anxiety disorders in women would be warranted given our finding 
that women were more likely to be prescribed antidepressants independent of symptom 
indications.
Better medication treatment of the initial illness episode raises the possibility of better acute 
and long-term outcomes. An important first-episode research question is whether promoting 
more evidence-based care does indeed improve outcomes and, if it does, what level of 
adherence to evidence-based practice is required.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Factors Associated with Prescription Patterns Log Odds Ratios and 95% Credible 
Intervals
Odds ratios in aqua are from multivariate analyses with selected % of 50% or greater but 
less than 75% (some evidence of association)
Odds ratios in green are from multivariate analyses with selected % of 75% or greater but 
less than 95% (positive evidence of association)
Odds ratios in red are from multivariate analyses with selected % of 95% or greater but less 
than 99% (strong evidence of association)
Antipsychotic prescription = prescription of one or more antipsychotics versus no 
antipsychotic prescribed
2 or more antipsychotics = prescription for 2 or more antipsychotics among subjects 
prescribed antipsychotics. Multiple formulations of the same antipsychotic were counted as 
a single antipsychotic.
Long acting antipsychotic = prescription for long acting antipsychotic or a long acting 
antipsychotic plus an oral antipsychotic among subjects prescribed antipsychotics
1st generation antipsychotic = prescription for a first generation antipsychotic or both a first 
and second generation antipsychotic among subjects prescribed antipsychotics
Risperidone prescription = prescription for risperidone among subjects prescribed only 1 
antipsychotic. Multiple formulations of the same antipsychotic were counted as a single 
antipsychotic.
Olanzapine prescription = prescription for olanzapine among subjects prescribed only 1 
antipsychotic. Multiple formulations of the same antipsychotic were counted as a single 
antipsychotic.
Antidepressant prescription = prescription for one or more antidepressants.
Caucas = Caucasian
Others = racial categories other than Caucasian and African-American
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Non-Hisp. = not of Hispanic ethnicity
Psych. NOS = psychosis NOS
SCZ = schizophrenia
SCZform = schizophreniform
SCzaff = schizoaffective disorder
Pvt = private
Anxty or Depr. Symps (N-Y) = presence of anxiety or depressive symptoms (not present 
versus present)
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Figure 2. Factors Associated with Dosing Patterns For Oral Risperidone or Olanzapine Beta and 
Z Scores and 95% Credible Intervals
Dosing data (expressed as total daily dose) are from prescriptions requiring patients to take a 
single antipsychotic solely in an oral formulation
Doses in aqua are from multivariate analyses with selected % of 50% or greater but less than 
75% (some evidence of association)
CrI = Credible Interval
Caucas = Caucasian
Others = racial categories other than Caucasian and African-American
AA = African-American
Hisp = Hispanic
Non-Hisp. = not of Hispanic ethnicity
Psych. NOS = psychosis NOS
SCZ = schizophrenia
SCZform = schizophreniform
SCzaff = schizoaffective disorder
Smoking = smoking cigarettes at study entry
Alcohol, Marijuana and Other drugs = use of these substances at study entry
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Table 1
Characteristics of 404 RAISE-ETP Subjects
Mean 95% CI Median
Age 23.6 years (23.1, 24.1) 22 years
Number Percent of subjects




American Indian N=22 5.4%
Asian N=12 3%
Pacific Islander N=1 0.2%
Hispanic ethnicity N=73 18.1%
Had a psychiatric hospitalization prior to enrollment N=316 78.2%
Diagnosis at study entry
schizophrenia N=214 53%
schizophreniform disorder (provisional) N=57 14.1%
schizophreniform disorder (definite) N=10 2.5%
schizoaffective disorder, bipolar type N=24 5.9%
schizoaffective disorder, depressive type N=57 14.1%
brief psychotic disorder N=2 0.5%
psychotic disorder NOS N=40 9.9%




other drugs of abuse1 N=10 2.5%






private or private and public N=82 20.4%
public only N=127 31.7%
no insurance N=173 43.1%
Insurance status not known by subject N=19 4.7%
1
status not assessed for 1 subject
2
status not assessed for 3 subjects
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Table 2
Frequency Of Prescription Of Major Medication Classes1
Medication class Number of subjects prescribed a class Percent of all subjects
No medication 48 11.9%
Only medications for general medical conditions 3 0.7%
Antipsychotics 337 83.4%
Antidepressants 129 31.9%
Mood stabilizer 37 9.2%
Anti-anxiety agent 42 10.4%
Sedative hypnotic 20 5.0%
Opiate analgesics 7 1.7%
Opioid replacement addiction medications 2 0.5%
Stimulants 5 1.2%
Non-stimulant ADHD medication 1 0.2%
α2 adrenergic agonist 3 0.7%
1
subjects could be prescribed more than 1 agent in a class
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